Effects of Albumin Supplements on In-Hospital Mortality in Patients with Sepsis or Septic Shock: A Systemic Review and Meta-Analysis

Pei Liu, Deyuan Zhi, Yajun Wang, Jin Lin, Meng Zhang, and Meili Duan

Department of Critical Care Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Correspondence should be addressed to Meili Duan; dmeili@ccmu.edu.cn

Received 21 July 2022; Accepted 22 September 2022; Published 10 October 2022

Academic Editor: Shuli Yang

Copyright © 2022 Deyuan Zhi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the clinical effects of albumin supplements on the basis of crystalloid solution in patients with sepsis or septic shock.

Methods. The online databases including PubMed, Web of Science, Cochrane Library, and EMBASE were comprehensively searched from inception to June 28, 2021, with the keywords including “albumin,” “sepsis,” or “septic shock.” Retrospective cohort (RC) and randomized controlled trials (RCT) were included for analysis. Two authors independently searched and analyzed the literature. The in-hospital mortality at 7 days and 28 days, duration of mechanical ventilation, renal replacement therapy, length of ICU stay, and length of hospital stay were compared between patients with albumin supplements and crystalloid solution and those with crystalloid alone.

Results. A total of 10 studies with 6463 patients were eventually included for meta-analysis. In-hospital mortality of patients at 7 days (OR = 1.00, 95% CI: 0.81–1.23) and 28 days (OR = 1.02, 95% CI: 0.91–1.13) did not show a significant difference between the two groups of patients. Also, the pooled results demonstrated no significant differences in duration of mechanical ventilation (OR = 0.29, 95% CI: −0.05–0.63), renal replacement therapy (WMD = 1.15, 95% CI: 0.98–1.35), length of ICU stay (WMD = −0.07, 95% CI: −0.62–0.48), and length of hospital stay (WMD = −0.09, 95% CI: −0.70–0.52) between patients receiving albumin plus crystalloid solution and those with crystalloid solution alone. Conclusion. Albumin supplements on the basis of crystalloid solution did not improve the 7-day and 28-day-hospital mortality in patients with sepsis or septic shock compared with those with crystalloid solution alone.

1. Introduction

Severe infections often lead to septic shock, which refers to sepsis syndrome with shock caused by microorganisms and toxins or metabolites [1]. Toxins and cell wall products in the lesions of septic shock patients invade the blood circulation, directly activate the host cells and humoral systems, synthesize and release endogenous mediators and cytokines, and act on important organs, tissues, and systems of the body, thereby seriously affecting the perfusion of these organs [2]. Severe infection-induced septic shock always leads to ischemia and hypoxia in tissue cells, increases the risk of metabolic disorders and dysfunctions of important organs and tissues, and even severe multiorgan failure in a small number of patients [3]. In clinical practice, it is difficult to treat septic shock. Since there is a high risk of death, most patients have a poor prognosis. In addition to actively controlling infection, the treatment of septic shock should also include supplementation of blood volume, correction of acidosis, adjustment of vasomotor function, elimination of blood cell aggregation, prevention of circulatory stasis, and maintenance of important organ functions [4]. The most important issue for successful treatment is to restore the normal blood perfusion, internal environment, and metabolism of the vital organs of the body [5]. Adequate fluid resuscitation in the early stage to maintain effective vascular volume and tissue perfusion can significantly improve the prognosis of patients with sepsis. Crystalloid solutions are frequently used for fluid resuscitation in critically ill patients due to their advantages such as effectiveness and low cost and availability. The crystalloid solution is composed of small molecules such as
2. Materials and Methods

2.1. Search Strategy and Literature Inclusion. We performed this systematic review and meta-analysis strictly in accordance with the requirements in Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [10]. The online databases including PubMed, Web of Science, Cochrane Library, and EMBASE were comprehensively searched with the keywords including “albumin,” “sepsis,” or “septic shock.” The retrieved literature was published from inception to June 28, 2021. Two authors independently searched and included the studies. All articles were firstly reviewed by title and abstract, and the potentially eligible studies were further reviewed by reading the full text. A study was eventually included if the inclusion and exclusion criteria were met. If different opinions occurred for the article, a senior researcher in the field was asked for further evaluation and determination of the inclusion or exclusion of the article.

2.2. Inclusion and Exclusion Criteria. Studies meeting the following criteria were eligible for inclusion: (1) the study design was prospective; (2) the study population was adult patients with sepsis or septic shock; (3) the intervention: patients in the study group were given albumin on the basis of crystalloid solution for fluid resuscitation, and patients in the control group were only given crystalloid solution for fluid resuscitation; (4) main outcome was in-hospital mortality at 7 days, 28 days or 90 days. Studies with one of the following criteria were excluded: (1) reduplicated studies; (2) data were inadequate; (3) case reports, reviews, and conference abstracts.

2.3. Data Extraction. For each eligible study, the authors, study periods, age of patients, study design, diseases, sample size, albumin concentration, crystalloid, follow-up, and outcomes were collected and recorded for further analysis.

2.4. Main Outcomes. The main outcomes in this systemic review and meta-analysis were in-hospital mortality of patients at 7 days, 28 days, or 90 days. Duration of mechanical ventilation, length of intensive care unit (ICU) stay and length of hospital stay, and renal replacement therapy were also collected and investigated.

2.5. Evaluation of Study Quality. The revised Cochrane risk of bias tool (RoB2.0) was used for evaluating the quality of included studies. The risk of bias was shown in Table 1 for details. In order to assess the publication bias, funnel plots were drawn and visually evaluated the symmetry of the plots.

2.6. Statistical Analyses. In this study, Stata 14.0 and Review Manager 5.0 software were applied for analysis. The ORs and 95% confidence interval (95% CI) were used to compare the effect of albumin in addition to the crystalloid solution on in-hospital mortality at 7 days and 28 days, as well as renal replacement therapy between the two groups. Weighted mean difference (WMD) and 95% CI were used to compare the duration of mechanical ventilation, length of ICU stay, and length of hospital stay between patients with albumin supplements and crystalloid solution and those with crystalloid alone. In order to evaluate the heterogeneity among different studies, we used the Cochran Q test and I² statistic for determining the type of effect model used. If \( P < 0.01 \) in the Q test or \( I^2 \text{ statistic} > 50\% \), a random-effect model was used since there was significant heterogeneity. Otherwise, a fixed-effect model was adopted.

3. Results

3.1. Study Characteristics. According to the aforementioned keywords used in searching the literature, a total of 201 potentially relevant articles were preliminarily obtained. After reviewing the title and abstract of these articles, 175 irrelevant articles were excluded. For the remaining 26 articles, there were 3 articles with repeated research, 4 articles with incomplete data for meta-analysis, 6 articles of reviews or systemic reviews, and 3 irrelevant studies. Eventually, ten studies [8, 11–19], which were published between 2004 and 2021, were included for further analysis. The characteristics of these studies were shown in Table 1 for details. A total of 6463 patients were included, in which 2979 patients (46.1%) in the study group received albumin supplement and crystalloid solution for fluid resuscitation, and 3484 patients (53.9%) in the control group were given crystalloid solution such as saline alone for resuscitation. (see Table 2).
| Study          | Study period | Age median (IQR) | Study type | Patients | Sample size (study/control) | Albumin (%) | Crystalloid | Follow-up                        | Outcome (study vs. control, %)             | Risk |
|---------------|--------------|------------------|------------|----------|-----------------------------|--------------|-------------|-------------------------------|------------------------------------------|------|
| Chou et al 2009 | N/A          | RC               | Sepsis     | 133 (52/81) | 25% albumin                 | N/A          |             | 28-day mortality               | 48.1% (25/52) vs. 51.9% (42/81)            | M    |
| Annane et al 2013 | Study: 63 (50–76) Control: 63 (50–75) | RCT | Sepsis     | 616 (59/557) | 4%, 5%, 20% or 25% albumin   | Isotonic or hypertonic saline |             | 28-day and 90-day mortality   | 28-day: 32.2% (19/59) vs. 28.2% (157/557) 90-day: 37.3% (22/59) vs. 35.4% (197/557) | L    |
| Park et al 2019  | Study: 62 (51–70) Control: 61 (52–70) | RCT | Sepsis and Septic shock | 360 (180/180) | 4% albumin                   | Lactated Ringer’s |             | 7-day and 28-day mortality     | 7-day: 25.6% (46/180) vs. 22.2% (40/180) 28-day: 53.3% (96/180) vs. 46.1% (83/180) | L    |
| Caironi et al 2014 | Study: 70 (57–77) Control: 69 (59–77) | RCT | Sepsis and Septic shock | 1810 (903/907) | 20% albumin                  | N/A          |             | 28-day and 90-day mortality   | 28-day: 31.8% (285/895) vs. 32.0% (288/900) 90-day: 41.1% (365/888) vs. 43.6% (389/893) | L    |
| Finfer et al 2011 | Study: 60.5 ± 17.2 Control: 61.0 ± 17.1 | RCT | Sepsis and Septic shock | 1218 (603/615) | 4% albumin                   | 0.9% sodium chloride |             | 28-day mortality               | 30.7% (185/603) vs. 35.3% (217/615)         | L    |
| Liu et al 2021  | Study: 67 (56–77) Control: 67 (54–77) | RCT | Sepsis and Septic shock | 835 (286/549) | 5% or 20% albumin            | N/A          |             | 28-day mortality               | 35.7% (102/286) vs. 31.7% (174/549)         | M    |
| Alexander et al 2021 | Study: 59 (51–67) Control: 59 (50–68) | RCT | Septic shock | 360 (335/335) | 25% albumin                  | N/A          |             | 28-day mortality               | 46.9% (157/335) vs. 44.8% (150/335)         | M    |
| Charpentier et al 2011 | N/A         | RCT | Septic shock | 792 (399/393) | 20% albumin                  | 0.9% sodium chloride |             | 28-day mortality               | 24.1% (96/399) vs. 26.2% (103/393)          | L    |
| Veneman et al 2004 | N/A          | RCT | Sepsis     | 31 (8/25)    | 20% albumin                  | 0.9% sodium chloride |             | 28-day mortality               | 62.5% (5/8) vs. 56.0% (14/25)              | H    |
| Philips et al 2021  | Study: 49.4 ± 12.1 Control: 48.2 ± 10.6 | RCT | Sepsis and Septic shock | 308 (154/154) | 5% albumin                   | 0.9% sodium chloride |             | 7-day mortality                | 43.5% (87/154) vs. 38.3% (95/154)           | M    |

IQR: interquartile range; RC: retrospective cohort; RCT: randomized controlled trials; M: moderate risk; L: low risk; H: high risk.
3.2. Effect of Albumin Supplements on In-Hospital Mortality. In order to evaluate the effect of albumin supplements on the in-hospital mortality of patients with sepsis or septic shock, we summarized the relevant data by meta-analysis. Three studies [15, 17, 18] assessed the mortality of patients at 7 days, and no statistically significant difference was detected between the two groups of patients according to the results of pooled analysis (Figure 1, OR = 1.00, 95% CI: 0.81–1.23). Nine studies [8, 11–17, 19] explored the mortality of patients at 28 days, and the pooled result showed that the mortality was not statistically different between patients with albumin supplements and those without supplements (Figure 2, OR = 1.02, 95% CI: 0.91–1.13). Funnel plots did not find significant publication bias of these studies (Supplementary Figures 1 and 2). Further subgroup analysis with 4 studies [11–13, 16] for patients with septic shock showed that albumin supplements did not affect the 28-day mortality of these patients (Supplementary Figure 3, OR = 1.06, 95% CI: 0.88–1.28).

3.3. Effect of Albumin Supplement on Duration of Mechanical Ventilation, Renal Replacement Therapy, Length of ICU Stay, and Hospital Stay. As for other outcomes including duration of mechanical ventilation, renal replacement therapy, length of ICU stay, and length of hospital stay, a total of 3 studies [8, 15, 16], 4 studies [8, 15–17], 4 studies [8, 15–17], and 4 studies [8, 15–17], respectively, investigated the effects of albumin supplement on these parameters. Interestingly, the pooled results did not show significant differences in the duration of mechanical ventilation (Figure 3, SMD = 0.29, 95% CI: −0.05–0.63), renal replacement therapy (Figure 4, OR = 1.15, 95% CI: 0.98–1.35), length of ICU stay (Figure 5, WMD = −0.07, 95% CI: −0.62–0.48), and length of hospital stay (Figure 6, WMD = −0.09, 95% CI: −0.70–0.52) between patients receiving albumin plus crystalloid solution and those with crystalloid solution alone.

4. Discussion

In this study, we performed a systemic review and meta-analysis of the currently available literature on supplementation of albumin in addition to a crystalloid solution for the treatment of patients with sepsis. The pooled analysis did not find significant differences between the study group and control group in the 7-day mortality, 28-day mortality, duration of mechanical ventilation time, renal replacement therapy, length of ICU stay, and total hospital stay. These results indicate albumin and crystalloid as resuscitation fluids did not differ in clinical outcomes in adult patients with sepsis or septic shock, and there is no significant clinical benefit with the use of albumin. Our study provides new insights into the clinical decision-making on the selection of agents for fluid resuscitation in patients with sepsis.

Sepsis is a severe stage of infection, with high mortality and poor prognosis during hospitalization. Clinically, catecholamine vasoconstrictor drugs and fluid resuscitation are often given to patients with septic shock. However, when the body is in a state of persistent infection, the response of blood vessels to the catecholamine drugs is reduced, and the treatment effect is limited. Early and effective fluid resuscitation is one of the most important widely used clinical treatment strategies. However, the selection of colloid or crystalloid as the resuscitation fluid has been controversial for a long time. Crystalloids mainly include various concentrations of sodium chloride solution, Ringer’s solution, and equilibrium solution, while human albumin is a common colloidal solution preparation.

Albumin is a negatively charged, small molecular weight, nonglycosylated serum protein with functions including substance binding and transport, enzymatic activity, and antioxidation [20]. Albumin is mainly synthesized and secreted by hepatocytes in the liver, secreted into the sinusoids, and then enters the blood circulation. The half-life of albumin is relatively long, for generally 17–20 days, after which degraded in muscle, liver, and kidney [21]. Albumin can bind a variety of endogenous and exogenous compounds, such as fatty acids, metal ions, metabolites, and drugs, which suggest that albumin may be used for the treatment of septic shock [22]. The occurrence and development of septic shock are affected by many factors, and it is a pathophysiological process in which many cytokines participate together. Aerobic metabolism is a normal physiological process of the body, but for patients with septic shock, aerobic metabolism occurs during treatment, and some of the intermediate products may cause the accumulation of toxic substances, such as reactive oxygen species and reactive nitrogen species, causing cell damage and dysfunction, which is also one of the main causes of death in patients with septic shock during treatment [23].

| Subgroup analysis | Studies | Pooled results | Heterogeneity |
|------------------|---------|----------------|---------------|
| Albumin concentration | | Effect size (95% CI) | P value | I² | P value |
| 4%-5% | 4 | 1.01 (0.86–1.20) | 0.861 | 54.0% | 0.089 |
| 20%-25% | 5 | 1.002 (0.88–1.18) | 0.798 | 0% | 0.461 |
| Sample size >650 | 5 | 0.99 (0.88–1.11) | 0.834 | 35.3% | 0.186 |
| ≤650 | 4 | 1.23 (0.92–1.66) | 0.164 | 0% | 0.555 |
| Study type RCT | 6 | 0.96 (0.85–1.10) | 0.576 | 27.7% | 0.227 |
| Retrospective study | 3 | 1.17 (0.95–1.43) | 0.139 | 0% | 0.668 |
Figure 1: Forest plot of odds ratio and 95% confidence interval on 7-day-in-hospital mortality of included studies.

Figure 2: Forest plot of odds ratio and 95% confidence interval on 28-day-in-hospital mortality of included studies.

Figure 3: Forest plot of weighted mean difference and 95% confidence interval on the duration of mechanical ventilation of included studies.
Theoretically, albumin can remove a variety of reactive oxygen species and reactive nitrogen produced by different ways, reduce the accumulation of toxic substances in patients, reduce cell damage and the risk of organ dysfunction [24]. In addition, albumin can combine with nitric oxide, bilirubin, and other substances with antioxidant effects to play an antioxidant role; meanwhile, many metal ions such as copper and iron can combine with albumin to catalyze...
Evidence-Based Complementary and Alternative Medicine

and reduce the body’s peroxidative damage [25]. In addition to albumin therapy, patients with septic shock will be treated with various other drugs during the treatment period. The cysteine binding mechanism on the amino acid sequence of albumin indicates that it may enhance the clinical efficacy of drugs in septic shock. However, our results in this study did not find significant differences in various clinical outcomes including 7-day and 28-day mortality, mechanical ventilation, renal replacement therapy, length of ICU stay, and hospital stay. Patients with septic shock did not benefit from the application of albumin. Therefore, more studies are needed to further confirm the significance of albumin administration in patients with sepsis.

Insufficiency of circulating blood volume is the main manifestation of infectious patients. It is mostly caused by the large opening of the venous vascular bed and the decrease in peripheral vascular resistance, resulting in abnormal distribution of blood flow. Meanwhile, severe leakage of capillaries can lead to severe hypoperfusion. So, reasonable and effective fluid resuscitation is of great clinical importance for these critically ill patients [26]. A previous study found that when the perfusion pressure was severely insufficient, the body’s compensatory ability cannot resist the occurrence of tissue edema, thereby further increasing the risk of tissue edema. The serious insufficiency of perfusion pressure will lead to pulmonary edema and increase the risk of in-hospital mortality [27]. Reasonably improving tissue hypoperfusion and relieving tissue ischemia and hypoxia is of great significance for improving patient prognosis and reducing the risk of death. The maintenance of colloid osmotic pressure has a positive significance in the treatment of septic shock [28]. The negative charge on the surface of albumin can attract sodium ions and play a role in retaining water. Also, albumin can maintain 70% to 80% of the colloidal osmotic pressure in plasma at normal levels [29]. Since the results of this study showed that albumin supplements did not improve the clinical prognosis of patients with sepsis, it is worth exploring the role of albumin on osmotic pressure in the conditions of sepsis.

Most patients with septic shock are accompanied by severe organ dysfunction, and a small number of patients may be combined with multiple organ failures. The continuous decline of organ function is the key reason for the high risk of death in patients. Therefore, during the systemic treatment of septic patients, protection of the organ function, and prevention of the damage to the normal organ by sepsis is also the key to treatment [27]. Albumin is considered to be effective in improving blood perfusion of organs, inhibiting the occurrence of inflammatory reactions, and combining with drugs used in comprehensive treatment, thereby play a role in protecting the important organs. A previous study found that the combined use of human albumin and cefotaxime sodium can reduce the damage to the kidneys caused by other drugs during treatment, and greatly reduce the mortality rate of patients [30]. However, our results showed that the albumin supplement did not influence the renal replacement therapy in patients with sepsis, suggesting that albumin may act on other roles for the important organs. In addition, studies have found that in the process of shock and resuscitation in critically ill patients, the use of 25% human albumin can reduce damage to lung tissue by regulating the expression of inflammatory factors in endothelial cells, thereby reducing damage to lung tissue [31].

Hypoalbuminemia is an independent risk factor for severe comorbidities and death in patients with septic shock [32]. Whether the role of human albumin in the treatment of hypoalbuminemia is reliable in septic shock has always been a hot topic of clinical debate [33]. A previous study found that the use of human albumin in critically ill patients did not affect the mortality rate, but for patients with septic shock and severe burn shock, the use of human albumin may increase the risk of death [30]. A study of 6997 critically ill patients compared 0.9% sodium chloride injection with human serum albumin for fluid resuscitation. The results showed that there was no statistically significant difference in mortality and treatment duration between the two groups [34]. Therefore, albumin and crystalloid have no difference in the prognosis of adult patients with sepsis and septic shock. In addition, when paying attention to the resuscitation effect of human albumin, it should also be fully considered that albumin may increase medical costs and the risk of transfusion of blood products.

4.1. Limitations. This study has some limitations. First, the number of eligible studies is relatively small, especially for those investigating the 7-day-in-hospital mortality, duration of mechanical ventilation, renal replacement therapy, length of ICU stay, and length of hospital stay. Second, the duration of follow-up of patients is relatively short, so the results of this study are limited to short-term prognosis. In the future, more randomized controlled studies (RCTs) with long-term follow-ups are needed to further explore the role of albumin supplements in these critically ill patients. Meanwhile, different evidence weights should be paid special attention to when both RCT and non-RCT studies (NRS) were included for analysis [35]. Third, since the concentrations of albumin used in different studies are varied, it inevitably causes a certain bias in the results. Besides, the subgroup/sensitivity analysis restricting to those with low albumin levels can be performed to exhibit the effect of albumin supplements in patients with low albumin levels. More strict and unified RCTs may further confirm the conclusions in this study.

5. Conclusion

In conclusion, albumin supplements on the basis of crystalloid solution did not improve the 7-day and 28-day-in-hospital mortality in patients with sepsis or septic shock compared with those with crystalloid solution alone. Also, albumin did not affect the duration of mechanical ventilation, renal replacement therapy, length of ICU stay, and length of hospital stay in these patients.

Data Availability

The data used to support the findings of this study are included within the article.
Disclosure

Pei Liu and Deyuan Zhi are the co first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was supported by Beijing Hospitals Authority Innovation Studio of Young Staff code: 202102.

Supplementary Materials

Supplementary Figure 1. Funnel plot of publication bias of included studies investigating the 28-day-in-hospital mortality. Supplementary Figure 2. Begg’s funnel plot of publication bias of included studies investigating the 28-day-in-hospital mortality. Supplementary Figure 3. Forest plot of odds ratio and 95% confidence interval on 28-day-in-hospital mortality of patients with septic shock. (Supplementary Materials)

References

[1] Z. Zhang, Y. Hong, N. Liu, and Y. Chen, “Association of do-not-resuscitate order and survival in patients with severe sepsis and/or septic shock,” *Intensive Care Medicine*, vol. 43, no. 5, pp. 715–717, 2017.

[2] A. Brunse, P. Worsoe, S. E. Pors, K. Skovgaard, and P. T. Sangild, “Oral supplementation with bovine colostrum prevents septic shock and brain barrier disruption during bloodstream infection in preterm newborn pigs,” *Shock*, vol. 51, no. 3, pp. 337–347, 2019.

[3] A. F. Lago, A. S. de Oliveira, H. C. D. de Souza, J. S. da Silva, A. Basile-Filho, and A. C. Gastaldi, “The effects of physical therapy with neuromuscular electrical stimulation in patients with septic shock: study protocol for a randomized cross-over design,” *Medicine (Baltimore)*, vol. 97, no. 6, Article ID e9736, 2018.

[4] C. Laroye, S. Gibot, L. Reppel, and D. Bensoussan, “Concise review: mesenchymal stromal/stem cells: a new treatment for sepsis and septic shock?” *Stem Cells*, vol. 35, no. 12, pp. 2331–2339, 2017.

[5] K. R. Genga, T. Shimada, J. H. Boyd, K. Walley, and J. Russell, “The understanding and management of organism toxicity in septic shock,” *Journal of Innate Immunity*, vol. 10, no. 5-6, pp. 502–514, 2018.

[6] J. L. Vincent and L. Gottin, “Type of fluid in severe sepsis and septic shock,” *Minerva Anestesiologica*, vol. 77, no. 12, pp. 1190–1196, 2011.

[7] H. Rosjo, S. Masson, P. Caironi et al., “Prognostic value of secretoneurin in patients with severe sepsis and septic shock: data from the albumin Italian outcome sepsis study,” *Critical Care Medicine*, vol. 46, no. 5, pp. e404–e410, 2018.

[8] P. Caironi, G. Tognoni, S. Masson et al., “Albumin replacement in patients with severe sepsis or septic shock,” *New England Journal of Medicine*, vol. 370, no. 15, pp. 1412–1421, 2014.

[9] S. Finfer, “Reappraising the role of albumin for resuscitation,” *Current Opinion in Critical Care*, vol. 19, no. 4, pp. 315–320, 2013.

Evidence-Based Complementary and Alternative Medicine

[10] D. Moher, L. Shamseer, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement,” *Systematic Reviews*, vol. 4, p. 1, 2015.

[11] M. P. Alexander, K. K. Mangalaparthi, A. K. Madugundu et al., “Acute kidney injury in severe COVID-19 has similarities to sepsis-associated kidney injury: a multi-omics study,” *Mayo Clinic Proceedings*, vol. 96, no. 10, pp. 2561–2575, 2021.

[12] D. Annane, S. Siami, S. Jaber et al., “Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial,” *JAMA*, vol. 310, no. 17, pp. 1809–1817, 2013.

[13] S. Charpentier, J. L. Ducasse, M. Cournot et al., “Clinical assessment of ischemia-modified albumin and heart fatty acid-binding protein in the early diagnosis of non-ST-elevation acute coronary syndrome in the emergency department,” *Academic Emergency Medicine*, vol. 17, no. 1, pp. 27–35, 2010.

[14] C. D. Chou, H. W. Yien, D. M. Wu, and C. D. Kuo, “Albumin administration in patients with severe sepsis due to secondary peritonitis,” *Journal of the Chinese Medical Association*, vol. 72, no. 5, pp. 243–250, 2009.

[15] The SAFE Study Investigators, S. Finfer, S. McEvoy et al., “Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis,” *Intensive Care Medicine*, vol. 37, no. 1, pp. 86–96, 2011.

[16] C. Liu, H. Li, Z. Peng et al., “Inclusion of albumin in the initial resuscitation of adult patients with medical sepsis or septic shock: a propensity score-matched analysis,” *Shock*, vol. 56, no. 6, pp. 956–963, 2021.

[17] C. H. L. Park, J. P. de Almeida, G. Q. de Oliveira et al., “Lactated Ringer’s versus 4% albumin on lactated Ringer’s in early sepsis therapy in cancer patients: a pilot single-center randomized trial,” *Critical Care Medicine*, vol. 47, no. 10, pp. e798–e805, 2019.

[18] C. A. Philips, R. Maiwall, M. K. Sharma et al., “Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial,” *Hepatology International*, vol. 15, no. 4, pp. 983–994, 2021.

[19] T. F. Veneman, J. O. Nijhuis, and A. J. J. Woottiez, “Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial,” *Wiener Klinische Wochenschrift*, vol. 116, no. 9-10, pp. 305–309, 2004.

[20] P. Das, S. K. Chaudhari, A. Das, S. Kundu, and C. Saha, “Interaction of flavonols with human serum albumin: a biophysical study showing structure-activity relationship and enhancement when coated on silver nanoparticles,” *Journal of Biomolecular Structure and Dynamics*, vol. 37, no. 6, pp. 1414–1426, 2019.

[21] P. Sarbadhikary and A. Dube, “Spectroscopic investigations on the binding of an iodinated chlorine p6-copper complex to human serum albumin,” *Photochemical and Photobiological Sciences*, vol. 16, no. 12, pp. 1762–1770, 2017.

[22] Q. Yuan, L. Li, Y. Pian et al., “Preliminary investigation of human serum albumin-Vβ inhibition on toxic shock syndrome induced by staphylococcus enterotoxin B in vitro and in vivo,” *Toxicol*, vol. 113, pp. 55–59, 2016.

[23] Y. Ishima, A. Inoue, J. Fang et al., “Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the
generation of nitric oxide,” Cancer Science, vol. 106, no. 2, pp. 194–200, 2015.
[24] C. Valerio, E. Theocharidou, A. Davenport, and B. Agarwal, “Human albumin solution for patients with cirrhosis and acute on chronic liver failure: beyond simple volume expansion,” World Journal of Hepatology, vol. 8, no. 7, pp. 345–354, 2016.
[25] Y. Zhang, P. Lee, S. Liang et al., “Structural basis of non-steroidal anti-inflammatory drug diclofenac binding to human serum albumin,” Chemical Biology & Drug Design, vol. 86, no. 5, pp. 1178–1184, 2015.
[26] C. H. Leung, C. A. Caldarone, F. Wang et al., “Remote ischemic conditioning prevents lung and liver injury after hemorrhagic shock/resuscitation: potential role of a humoral plasma factor,” Annals of Surgery, vol. 261, no. 6, pp. 1215–1225, 2015.
[27] D. B. Kell and E. Pretorius, “To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin?” Seminars in Thrombosis and Hemostasis, vol. 44, no. 3, pp. 224–238, 2018.
[28] F. B. Horowitz, R. L. Read, and L. L. Powell, “A retrospective analysis of 25% human serum albumin supplementation in hypoalbuminemic dogs with septic peritonitis,” Canadian Veterinary Journal, vol. 56, no. 6, pp. 591–597, 2015.
[29] D. C. Roopenian, B. E. Low, G. J. Christianson, G. Proetzel, T. J. Sproule, and M. V. Wiles, “Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs,” mAbs, vol. 7, no. 2, pp. 344–351, 2015.
[30] I. Roberts, K. Blackhall, P. Alderson, F. Bunn, and G. Schierhout, “Human albumin solution for resuscitation and volume expansion in critically ill patients,” Cochrane Database of Systematic Reviews, vol. 2011, no. 11, Article ID CD001208, 2011.
[31] A. H. Penn, M. A. Dubick, and I. P. Torres Filho, “Fatty acid saturation of albumin used in resuscitation fluids modulates cell damage in shock: in vitro results using a novel technique to measure fatty acid binding capacity,” Shock, vol. 48, no. 4, pp. 449–458, 2017.
[32] A. A. Schramko, R. T. Suojaranta-Ylinen, A. H. Kuitunen, S. I. Kukkonen, and T. T. Niemi, “Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial,” Anesthesia & Analgesia, vol. 108, no. 1, pp. 30–36, 2009.
[33] E. Damiani, C. Ince, F. Orlando et al., “Effects of the infusion of 4% or 20% human serum albumin on the skeletal muscle microcirculation in endotoxemic rats,” PLoS One, vol. 11, no. 3, Article ID e0151005, 2016.
[34] A. P. Delaney, A. Dan, J. McCaffrey, and S. Finfer, “The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis,” Critical Care Medicine, vol. 39, no. 2, pp. 386–391, 2011.
[35] Z. Zhang, L. Chen, P. Xu et al., “Effectiveness of automated alerting system compared to usual care for the management of sepsis,” NPJ Digital Medicine, vol. 5, no. 1, p. 101, 2022.